OBJECTIVE: To evaluate the effects of long term treatment of rheumatoid arthritis (RA) with high doses of intravenous immunoglobulins (IVIg). METHODS: Ten patients with active RA and prior unsuccessful treatment with at least one slow acting antirheumatic drug were treated with 400 mg/kg of IVIg for the first three days and then once a month for 12 months. Clinical evaluation and laboratory analysis were performed every month. Serum levels of tumour necrosis factor alpha (TNF alpha), soluble interleukin-2 receptor (sIL-2R), IL-1 alpha, IL-1 beta, IL-6 and interferon gamma (IFN gamma) were measured at baseline and at three monthly intervals for 15 months. RESULTS: Although laboratory parameters were not influenced by the treatment, a late but significant clinical improvement was observed after six months. Serial measurement of cytokines revealed a rapid and persistent decrease in serum TNF alpha and a late and significant reduction in sIL-2R concentrations. CONCLUSION: This study suggests that IVIg can ameliorate the symptoms and improve the functional capability of RA patients. This effect is associated with a partial modulation of serum concentrations of inflammatory cytokines and, more interestingly, with a late decrease in sIL-2R which correlated with the late reduction in disease activity.
OBJECTIVE: To evaluate the effects of long term treatment of rheumatoid arthritis (RA) with high doses of intravenous immunoglobulins (IVIg). METHODS: Ten patients with active RA and prior unsuccessful treatment with at least one slow acting antirheumatic drug were treated with 400 mg/kg of IVIg for the first three days and then once a month for 12 months. Clinical evaluation and laboratory analysis were performed every month. Serum levels of tumour necrosis factor alpha (TNF alpha), soluble interleukin-2 receptor (sIL-2R), IL-1 alpha, IL-1 beta, IL-6 and interferon gamma (IFN gamma) were measured at baseline and at three monthly intervals for 15 months. RESULTS: Although laboratory parameters were not influenced by the treatment, a late but significant clinical improvement was observed after six months. Serial measurement of cytokines revealed a rapid and persistent decrease in serum TNF alpha and a late and significant reduction in sIL-2R concentrations. CONCLUSION: This study suggests that IVIg can ameliorate the symptoms and improve the functional capability of RApatients. This effect is associated with a partial modulation of serum concentrations of inflammatory cytokines and, more interestingly, with a late decrease in sIL-2R which correlated with the late reduction in disease activity.
Authors: P Tugwell; C Bombardier; M Gent; K J Bennett; W G Bensen; S Carette; A Chalmers; J M Esdaile; A V Klinkhoff; G R Kraag Journal: Lancet Date: 1990-05-05 Impact factor: 79.321
Authors: J T Sharp; D Y Young; G B Bluhm; A Brook; A C Brower; M Corbett; J L Decker; H K Genant; J P Gofton; N Goodman Journal: Arthritis Rheum Date: 1985-12
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: P Barrera; A M Boerbooms; E M Janssen; R W Sauerwein; H Gallati; J Mulder; T de Boo; P N Demacker; L B van de Putte; J W van der Meer Journal: Arthritis Rheum Date: 1993-08
Authors: A Achiron; R Margalit; R Hershkoviz; D Markovits; T Reshef; E Melamed; I R Cohen; O Lider Journal: J Clin Invest Date: 1994-02 Impact factor: 14.808
Authors: N Svetlicky; S Kivity; Q Odeh; O Shovman; S Gertel; H Amital; O Gendelman; A Volkov; I Barshack; E Bar-Meir; M Blank; Y Shoenfeld Journal: Clin Exp Immunol Date: 2015-09-24 Impact factor: 4.330
Authors: F Nacci; A Righi; M L Conforti; I Miniati; G Fiori; D Martinovic; D Melchiorre; T Sapir; M Blank; Y Shoenfeld; A Moggi Pignone; M Matucci Cerinic Journal: Ann Rheum Dis Date: 2007-03-07 Impact factor: 19.103
Authors: Ulrike Harre; Stefanie C Lang; René Pfeifle; Yoann Rombouts; Sabine Frühbeißer; Khaled Amara; Holger Bang; Anja Lux; Carolien A Koeleman; Wolfgang Baum; Katharina Dietel; Franziska Gröhn; Vivianne Malmström; Lars Klareskog; Gerhard Krönke; Roland Kocijan; Falk Nimmerjahn; René E M Toes; Martin Herrmann; Hans Ulrich Scherer; Georg Schett Journal: Nat Commun Date: 2015-03-31 Impact factor: 14.919
Authors: Ajay Jain; Henrik S Olsen; Ravi Vyzasatya; Erin Burch; Yukimi Sakoda; Emmanuel Y Mérigeon; Ling Cai; Changwan Lu; Ming Tan; Koji Tamada; Dan Schulze; David S Block; Scott E Strome Journal: Arthritis Res Ther Date: 2012-08-20 Impact factor: 5.156
Authors: G Halpert; I Katz; M Blank; O Shovman; S Tarasov; K K Ganina; N Petrova; M Tocut; A Volkov; I Barshack; H Amital Journal: Clin Exp Immunol Date: 2020-10-26 Impact factor: 5.732